The Court also denied Perrigo’s motion for summary judgment based on non- infringement. The case will now proceed to trial with the trial date not having been set. With the temporary restraints lifted, Perrigo has commenced launching the product. As the first filer, this commences its 180 days of generic exclusivity.
Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp.
Joseph Papa, chairman and CEO of Perrigo, said: “We are excited about the launch of Clobetasol Foam, which reflects our on-going efforts to make quality healthcare more affordable for our customers.”